Systems and methods of the present disclosure include a five-layer environment consisting tremor management hardware, interface, control system, machine learning environment and cloud capabilities. These elements come together to implement program instructions and perform steps to: receive sensory data elements(s) for tremor stat(s), physiological and/or environmental state(s) of the user, user activities and state(s) of the tremor management hardware and based on these state(s) generate at least one actionable tremor mitigation action associated with historical tremor mitigation improvements recorded in a memory, and display at a user computing device the at least one actionable tremor mitigation action to a user, a healthcare provider, or both.

A method for measuring sound from vortices in the carotid artery comprising: a first and second quality control provisions, wherein the quality control compares detected sounds to pre-determined sounds, and upon confirmation of the quality control procedures, detecting sounds generated by the heart and sounds from vortices in the carotid artery for at least 30 seconds. A method for determining stenosis of the carotid artery in a human patient consisting of a first step of placing a sensing device comprising an array and three sensing elements onto the patient, wherein a first sensing element is placed near the heart and the two remaining sensing elements are placed adjacent to the carotid arteries; the sensing elements then measure sounds from each of the three sensing elements, resulting in sound from three channels. The sound is measured in analog and modified to digital format and then each of the three channels are analyzed before a power spectral density analysis is performed. The power spectral density graph reveals peaks that are not due to noise, that are then analyzed to provide for a calculation of percent stenosis or complete occlusion of the carotid artery.

The present invention relates to methods for tuning treatment parameters in movement disorder therapy systems. The present invention further relates to a system for screening patients to determine viability as candidates for certain therapy modalities, such as deep brain stimulation (DBS). The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of tuning a therapy device using objective quantified movement disorder symptom data acquired by a movement disorder diagnostic device to determine the therapy setting or parameters to be provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.

A serialized probe component for an optoacoustic device has a unique identifier associated therewith and includes, in an embodiment, an operative connection between a read-write memory and the optoacoustic device. Software adapted to generate and store logs in a read-write memory is executed on the optoacoustic device and stores logs concerning utilization of the serialized probe component on the read-write memory. A method for logging operational information concerning an optoacoustic device is further disclosed.

A medical monitoring unit for continuously monitoring a glucose value and a lactate value is provided. The monitoring unit comprises: a display unit, a first unit adapted to: receive a glucose/lactate/pyruvate signal based on a measured glucose/lactate/pyruvate value, transform the glucose signal into a graphically displayable glucose/lactate/pyruvate signal, and transmit the graphically displayable glucose/lactate/pyruvate signal to the display unit of the monitoring unit, and a second unit adapted to: receive a glucose/lactate/pyruvate signal based on a measured glucose/lactate/pyruvate value, transform the glucose/lactate/pyruvate signal into a graphically displayable glucose/lactate/pyruvate signal, and transmit the graphically displayable glucose/lactate/pyruvate signal to the display unit of the monitoring unit. Furthermore, a system comprising the monitoring unit, and a sensor unit for sensing glucose and/or lactate and/or pyruvate values, is provided, as well as a method for performing the steps made possible through the provided unit and method.

The invention relates to a medical electrode for recording bioelectrical signals from a muscle, in particular a cardiac muscle, via the skin of a human or animal. The medical electrode comprises: a metal contact (2) for connection to an electrode cable; an electrically conductive electrode plate (3) for receiving the bioelectrical signals; a contact means (4) for establishing an electrical contact between the electrode plate and the skin; and an electronic circuit (7) which comprises a memory (6) for storing electrode-related data.

Methods and systems are disclosed herein for a system configured to determine a position of a brain monitoring user device, and a brain state of a user. Based on the determined position and the determined brain state, the system provides access to a set of media guidance application operations corresponding to the determined brain state and to brain regions corresponding to the determined position of the brain monitoring user device.

A surgical instrument has a staple cartridge housing a plurality of staples and an anvil configured to capture tissue therebetween. The surgical instrument also has a firing assembly configured to deploy the plurality of staples into the captured tissue during a firing sequence, and a handle that includes an electric motor operably coupled to the firing assembly, wherein the electric motor is configured to motivate the firing assembly to deploy the plurality of staples into the captured tissue during the firing sequence, and a power pack. The power pack includes rechargeable battery cells configured to power the electric motor, at least one battery-cell health indicator, and an electronic control circuit configured to assess whether a subset of rechargeable battery cells is damaged during the firing sequence based on at least one measurement performed by the at least one battery-cell health indicator.

Systems and methods for processing sensor data and end of life detection are provided. In some embodiments, a method for determining the end of life of a continuous analyte sensor includes evaluating a plurality of risk factors using an end of life function to determine an end of life status of the sensor and providing an output related to the end of life status of the sensor. The plurality of risk factors may be selected from the list including the number of days the sensor has been in use, whether there has been a decrease in signal sensitivity, whether there is a predetermined noise pattern, whether there is a predetermined oxygen concentration pattern, and error between reference BG values and EGV sensor values.

Apparatus for transcutaneous electrical nerve stimulation in a user, the apparatus comprising: stimulation means for electrically stimulating at least one nerve; an electrode array connectable to said stimulation means, said electrode array comprising a plurality of electrodes for electrical stimulation of the at least one nerve, said electrodes having a pre-formed geometry and known electrode-skin contact area size when in complete contact with the user's skin; monitoring means electrically connected to said stimulation means for monitoring the impedance of the electrical stimulation through said electrode array; and analysis means for analyzing said impedance to estimate a change in the electrode-skin contact area.